Polio endgame complexity: updating expectations for nOPV2.

[1]  M. Pallansch,et al.  Immunogenicity of novel oral poliovirus vaccine type 2 administered concomitantly with bivalent oral poliovirus vaccine: an open-label, non-inferiority, randomised, controlled trial. , 2023, The Lancet. Infectious diseases.

[2]  K. Thompson.  Effectiveness of a new vaccine for outbreak response and the increasingly complicated polio endgame. , 2022, The Lancet. Global health.

[3]  K. Badizadegan,et al.  Outbreak response strategies with type 2-containing oral poliovirus vaccines , 2022, Vaccine.

[4]  Rachel L. Marine,et al.  Public Health Response to a Case of Paralytic Poliomyelitis in an Unvaccinated Person and Detection of Poliovirus in Wastewater — New York, June–August 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[5]  John O. Konz,et al.  Enabling accelerated vaccine roll-out for Public Health Emergencies of International Concern (PHEICs): Novel Oral Polio Vaccine type 2 (nOPV2) experience , 2022, Vaccine.

[6]  K. Thompson.  Polio eradication: what kind of world do we want? , 2021, The Lancet Infectious Diseases.

[7]  M. Pallansch,et al.  Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response , 2021, Vaccine.

[8]  K. Thompson,et al.  Lessons From the Polio Endgame: Overcoming the Failure to Vaccinate and the Role of Subpopulations in Maintaining Transmission , 2017, The Journal of infectious diseases.

[9]  R. D. Tebbens,et al.  Trends in the Risk of U.S. Polio Outbreaks and Poliovirus Vaccine Availability for Response , 2012, Public health reports.